Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 15/20 | 0.68 |
| ▸ | NMUR1 | Q9HB89 | 14/20 | 0.68 |
| ▸ | NPY1R | P25929 | 2/20 | 0.58 |
| ▸ | NPY2R | P49146 | 1/20 | 0.58 |
| ▸ | NPY4R | P50391 | 1/20 | 0.58 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.58 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.57 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31506919 | 0.89 | NMUR2 (0.59) | NMUR2NMUR1 | |
| SCHEMBL29698606 | 0.89 | NMUR2 (0.71) | NMUR2NMUR1 | |
| SCHEMBL29370026 | 0.89 | NMUR2 (0.71) | NMUR2NMUR1 | |
| SCHEMBL3539226 | 0.89 | NMUR2 (0.71) | NMUR2NMUR1 | |
| SCHEMBL29604581 | 0.86 | NMUR2 (0.77) | NMUR2NMUR1 | |
| SCHEMBL30712242 | 0.83 | OPRD1 (0.66) | NMUR2NMUR1 | |
| SCHEMBL29494603 | 0.82 | NMUR2 (0.66) | NMUR2NMUR1NPY1RNTSR2NTSR1 | |
| SCHEMBL29519178 | 0.82 | NMUR2 (0.79) | NMUR2NMUR1NPY1RNTSR2NTSR1 | |
| SCHEMBL30987365 | 0.82 | NMUR2 (0.57) | NMUR2NMUR1 | |
| SCHEMBL1674802 | 0.81 | NMUR2 (0.57) | NMUR2NMUR1NTSR2NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025133225-A1 | PHARMACEUTICAL COMBINATION OF PEPTIDE-GLY AND PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) | PAM THERAGNOSTICS GMBH (DE) | 2025-06-26 | — | — | WO | claimed |
| CN-119185569-A | Sustained release delivery system comprising a traceless linker | 诺华股份有限公司 | 2024-12-27 | — | — | CN | claimed |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | UNIV LELAND STANFORD JUNIOR (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260034192-A1 | USE OF GNRH ANTAGONISTS IN MAMMALS TO SYNCHRONIZE FOLLICULAR WAVE EMERGENCE | UNIV SASKATCHEWAN (CA) | 2026-02-05 | — | — | US | disclosed |
| US-20260021075-A1 | 2-PENTADECYL-2-OXAZOLINE AS AN OPIOID ADJUVANT TO PREVENT OR TREAT HYPERALGESIA | EPITECH GROUP S.P.A. (IT) | 2026-01-22 | — | — | US | disclosed |
| EP-4149556-B1 | PEG LIPIDOID COMPOUNDS | TRANSLATE BIO INC (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12514932-B2 | PEG lipidoid compounds | TRANSLATE BIO, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-12453759-B2 | Di-thioester cationic lipids | TRANSLATE BIO, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-12433949-B2 | Sustained release delivery systems comprising traceless linkers | NOVARTIS AG (CH) | 2025-10-07 | — | — | US | disclosed |
| EP-4618957-A1 | COMPOSITIONS COMPRISING OCTADECANEUROPEPTIDES (ODN) AND SYNTHETIC DERIVATIVES THEREOF AND METHODS OF USE FOR MODULATION OF FOOD INTAKE, OBESITY, BODY WEIGHT, NAUSEA, AND EMESIS | The Trustees of The University of Pennsylvania (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250288523-A1 | PEG LIPIDOID COMPOUNDS | TRANSLATE BIO INC (US) | 2025-09-18 | — | — | US | disclosed |
| US-20220233444-A1 | THIOESTER CATIONIC LIPIDS | TRANSLATE BIO, INC. | 2022-07-28 | — | — | US | disclosed |
| US-20220226244-A1 | MACROCYCLIC LIPIDS | TRANSLATE BIO INC (US) | 2022-07-21 | — | — | US | disclosed |
| US-20220226236-A1 | Pulmonary Delivery of MRNA to Non-lung Target Cells | RANA THERAPEUTICS, INC. | 2022-07-21 | — | — | US | disclosed |
| EP-4010328-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE CONFOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | Domain Therapeutics (FR) | 2022-06-15 | — | — | EP | disclosed |
| US-20220177423-A1 | CYSTINE CATIONIC LIPIDS | TRANSLATE BIO, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
| CN-114269730-A | 5-heteroaryl-pyridin-2-amine compounds as neuropeptide FF receptor antagonists | 多曼治疗学公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20220073944-A1 | MULTIMERIC CODING NUCLEIC ACID AND USES THEREOF | TRANSLATE BIO, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220071905-A1 | PEG LIPIDOID COMPOUNDS | TRANSLATE BIO, INC. | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | NMUR2 2031/4885NMUR1 2319/4885NPY1R 3820/4885 |
| US-20220177423-A1 | CYSTINE CATIONIC LIPIDS | SLC7A11, SLC7A1, SLC7A5 | NMUR2 2975/4885NMUR1 2927/4885NPY1R 3706/4885 |
| US-20220073944-A1 | MULTIMERIC CODING NUCLEIC ACID AND USES THEREOF | NSUN3, TRDMT1, NSUN2 | NMUR2 704/4885NMUR1 779/4885NPY1R 2241/4885 |
| US-20250288523-A1 | PEG LIPIDOID COMPOUNDS | LIPG, ABCB4, HDLBP | NMUR2 4782/4885NMUR1 4786/4885NPY1R 4399/4885 |
| US-12453759-B2 | Di-thioester cationic lipids | ACOT7, LYPLA2, LYPLA1 | NMUR2 3786/4885NMUR1 3983/4885NPY1R 4432/4885 |
| US-20220071905-A1 | PEG LIPIDOID COMPOUNDS | HDLBP, LIPG, ABCB4 | NMUR2 4789/4885NMUR1 4803/4885NPY1R 4400/4885 |
| US-20220233444-A1 | THIOESTER CATIONIC LIPIDS | CETP, ACOT7, LYPLA1 | NMUR2 4477/4885NMUR1 4420/4885NPY1R 3639/4885 |
| US-20260021075-A1 | 2-PENTADECYL-2-OXAZOLINE AS AN OPIOID ADJUVANT TO PREVENT OR TREAT HYPERALGESIA | OPRD1, OPRM1, OPRK1 | NMUR2 2236/4885NMUR1 3924/4885NPY1R 1715/4885 |
| US-12433949-B2 | Sustained release delivery systems comprising traceless linkers | ABCB11, ABCB1, GHRHR | NMUR2 2743/4885NMUR1 2571/4885NPY1R 645/4885 |
| US-20220226244-A1 | MACROCYCLIC LIPIDS | SGMS1, NPC1L1, ABCB4 | NMUR2 4085/4885NMUR1 4015/4885NPY1R 3830/4885 |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | ADAR, ZFR, SLIRP | NMUR2 1950/4885NMUR1 1964/4885NPY1R 1849/4885 |
| US-20260034192-A1 | USE OF GNRH ANTAGONISTS IN MAMMALS TO SYNCHRONIZE FOLLICULAR WAVE EMERGENCE | GNRHR, FSHR, PGF | NMUR2 1415/4885NMUR1 1887/4885NPY1R 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.